Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.
Marketing Status Prescription; Discontinued
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 70436-012; 70436-013; 50090-4806; 0054-0401; 46708-152; 70518-3195; 68382-469; 0591-3659; 71335-1815; 0054-0603; 70436-036; 71335-1753; 51407-023; 0591-4060; 50090-4388; 63304-191; 0591-3660; 14501-0068; 46708-153; 60687-607; 70771-1311; 68382-741; 71335-1975; 0054-0400; 51407-022; 63304-192; 63629-7524; 71335-1700; 70771-1312; 69766-025
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fatigue08.01.01.002--
Fear19.06.03.0010.001692%Not Available
Feeling abnormal08.01.09.0140.019880%Not Available
Feeling drunk08.01.09.0150.000846%Not Available
Feeling hot08.01.09.0090.000846%Not Available
Feeling jittery08.01.09.0160.002961%Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Food poisoning12.03.01.024; 11.07.02.001; 07.11.01.0070.001269%Not Available
Gait disturbance17.02.05.016; 08.01.02.002--
Gastrointestinal disorder07.11.01.0010.002538%Not Available
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009--Not Available
Gastrointestinal pain07.01.05.0050.000846%
Glaucoma06.03.01.0020.001269%
Glossodynia07.14.02.0010.000846%Not Available
Haematochezia24.07.02.012; 07.12.02.0030.000846%Not Available
Haemorrhagic disorder24.07.01.021; 01.01.03.004--Not Available
Hallucination19.10.02.0020.003807%
Hallucination, auditory19.10.02.0030.001692%Not Available
Head discomfort17.02.05.0270.000846%Not Available
Headache17.14.01.0010.025379%
Heart rate decreased13.14.04.0010.001269%Not Available
Heart rate increased13.14.04.0020.001692%Not Available
Hepatic failure09.01.03.0020.000331%
Hiccups22.02.04.002; 07.01.06.0090.000846%
Hostility19.05.01.0030.000846%Not Available
Hyperaesthesia17.02.06.0040.000846%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.008460%
Hypersensitivity10.01.03.0030.002961%
Hypersomnia17.15.01.001; 19.02.05.0010.001269%
Hypertension24.08.02.0010.003807%
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 11 Pages